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With the development of shorter-lived, organspecific radiopharmaceuticals, much of the manufacture and quality control of these products have
shifted from commercial manufactures to individual
nuclear medicine laboratories. Recognizing this fact,
the Nuclear Regulatory Commission (NRC) is encouraging quality assurance by proposing that "an
authorized physician may permit technicians and
other paramedical personnel to perform the preparation and quality control testing of radiopharmaceuticals ... " (I).
Cohen (2) has catagorized pharmaceutical controls into chemical, biological, and physical. Figure I
is a diagram of these controls. In each control a
degree of purity is implied and is often determined by
comparison to a standard.
Chemical controls.
A . Radiochemical purity. May be defined as that
portion of the stated radionuclide in the stated
chemical form. This can be assessed in the nuclear
medicine laboratory by several techniques. It is applicable to Tc 99m·pertechnetate compounds where
the degree of tag to an organ-specific molecule must
be evaluated.
Radiochemical impurities may be demonstrated
in those images where organs other than the target
organ are visualized due to a free (unbound) radioactive component of a labeled product. Visualization of
thyroid on lung imaging (Fig. 2) or stomach with
kidney (Fig. 3) a nd bone (Fig. 4) imaging are examples of these. Reagent "kits" labeled with
• Presented by Dr. Hirsch at the Postgraduate Course in Nuclear
. Medicine, February 25 , 1975 , in Williamsburg, Virginia.
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radionuclides should be at least 90% bound for optimum organ visualization. The assessment of
binding can be accomplished in the laboratory
by the use of gel filtration and/or thin-layer
chromatographic techniques. Labeled reagent kits
may contain small molecules (free Tc 99 m.
pertechnetate), larger labeled molecules, and a
reduced technetium fraction which is considered
neither free nor bound to an organ-specific molecule.
To determine the percentage of each component in
this three-phase system by employing the gel filtration
technique, 1-2 ,ul of the material is placed at the top
of a gel column and eluted with a suitable solvent.
Heavy molecules which do not enter the gel meshwork will be eluted first, after the void volume. Light
molecules will follow several milliters later. Reduced
technetium, if present, will bind to the gel and can
be removed by oxidation with 0.1 % H 2 0 2 . This fraction can be subsequently collected with additional
volumes of solvent. The fractionated volumes are
counted and quantitation of each component may be
determined.
Thin-layer chromatography employs the use of
suitable media strips to which is spotted 5,ul of the
radioactive material 2.5 cm from the bottom of the
strip. The strip is dried and placed in a developing
tank containing a suitable solvent system (Fig. 5).
The solvent is allowed to ascend the strip until the
front is at approximately 14 cm. Solvent systems
chosen provide for the bound material to remain approximately at the origin (point of application) while
free activity migrates to the level of the solvent front.
Using this method, Rf (reference factor) may be
determined. These factors are ratios of distance
57
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Fig. I-Diagram of the radiopharmaceutical controls.

traveled by the radioactive entities to that traveled
by the solvent front. Labeled molecule Rf are approximately 0-0.1 while that of free species 0.8-1.0. Solvent systems may be single or multiple components
and provide for good separation of labeled molecules
and free ionic species.
Strips are removed from developing tanks, air
dried, and analyzed for quantitation of components
in the sample. Strips may be cut into I cm widths and
placed into gamma well counters to determine
presence and, therefore, identity of activity on the
strip. The origin (2.5-3 .5 cm) of acceptable
radiopharmaceuticals contains 90% of the counts. A
radiochromatogram well adapter can be used and is
less time consuming (3). Radioscanchromatographs
can provide this information by producing a graph
with peaks of activity demonstrating location and
quantitation of radioactive components.
Figure 6 is a chromatograph of Tc 99 mPolyphosphate® (New England Nuclear) used as the
bone scanning agent in Figure 4. The chromatograph
demonstrates activity at the origin representing

Fig. 3-Tc••m-Renotec (Squibb) kidney image demonstrating
stomach uptake of free Tc••m-pertechnetate. (Image provided
courtesy Dr. H. T. Haden, McGuire VA Hospital, Richmond, Va.)

Tc99m-pertechnetate bound to phosphate complexes,
activity between origin and solvent front demonstrating reduced pertechnetate and/ or labeled metabolized phosphates, and a second but less prominent
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Fig. 2-1'"-macroaggregated albumin (Abbott) lung image
demonstrating thyroid uptake of free radioiodine.
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Fig. 4-Tc••m-Polyphosphate® (New England Nuclear) bone image demonstrating stomach uptake of free Tc••m·pertechnetate.
Increased activity in liver probably associated with a reduced
technetium species in blood pool.
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Recommended Chromotography Sol vents
Rf
Preeorotion

Solvent

Tc99m (Sn ) DTPA

Acetone

BTc

FTc

0. 0

Butyl acetate

o.o

l. 0
0. 8

M.E . K.

0.0

1.0

Methanol , 85%

0.0

0.8

Methanol, 85%

0.0

0.8

Tc99m - Pol yphosphate

Acetone
Butyl acetate

0.0
0.0

1.0
0.8

Renotec *

Butanol: Ethanol: Water
(2 :2: 1)

0. 1

0.7

Tc99m - Sulfur Colloid

Methanol, 85%

0. 1

l. 0

Tc99m (Sn ) Gluco heptonate
· Tc99m - HSA
Tc99m - MAA

*Eastman TLC Cellulose #6064 media; all others, Gelman !TLC
Type SG

Fig . 5-Chromatography solvent systems recommended for the
determination of bound (BTc) and free (FTc) components of
technetium-99m kit preparations. Each system provides reproducible Rf values used in the identification and quantitation of each
component.

peak at the solvent front demonstrating free
pertechnetate.
Figure 7 compares the chromatographs ofTc••m_
Polyphosphate® (NEN) to that of Osteoscan® (Proctor and Gamble). Technetium-99m-pertechnetate obtained from a 400 millicuries fission Mo""-Tc 99 m
generator was used to prepare each of the above bone
imaging agents. The Tc••m-Polyphosphate® chromatogram demonstrated 98.5% of the pertechnetate
bound to the phosphate complex. With Osteoscan®,
the chromatograph demonstrated a reduced and/ or
labeled metabolized phosphate component of approximately 40%. The manufacturer claimed that the nitrogen atmosphere in the vial was lost through the
rubber closure with oxidation of the Sn(II) reducing
agent. (Recently the manufacturer has adopted a
butyl rubber closure which has resolved this problem.)
Figure 8 is a chromatograph of Tc••m-SnGlucoheptonate® (NEN). With methyl ethyl ketone
(MEK) solvent, peak activity was found at the
origin corresponding to the bound component. No
free pertechnetate was demonstrated. The manufacturer claimed the material may be subject to colloid formation with some resultant localization of
activity in the liver. The material was chromato-

gramed in a physiologic saline solution demonstrating no colloid at the origin.
B. Carrier amount. May be defined as stable or
long-lived isotopes of the nuclide present at the time
of administration of the radiopharmaceutical. Carrier, if present in large quantities, alters the distribution of the nuclide in vivo or adds to radiation burden
if it is radioactive. Manufacturers prepare compounds that are "carrier-free." This has come to
mean that no other isotope of the nuclide has been intentionally added .
C . Buffer amount. The pH of radiopharmaceuticals should be adjusted to provide for stable
complexes as well as physiologic suitability. Most
radiopharmaceuticals are adjusted in the range of pH
4.0 to 8.8.
D. Total ions concentrations. Radiochemical
solutions after production may contain various
metals or metaloids as contaminants. These contaminants may be imparted from apparatus and reagent
materials even if very pure. Complexation of the
radiochemical with these traces give chemically unstable radioactive solutions. A standard of 80µg / ml
of these ions has been set; however, the current state
of the art is to prepare products with less than
lµg / ml.
Of the potential nonradioactive ionic impurities
present in Tc••m-pertechnetate eluent, aluminum [Al
(III)] has produced the most concern. Toxicology of
Al (III) of potential doses administered appears
minimal (Fig . 9); however, it has been reported to
cause flocculation of Tc 99m-sulfur colloid preparations as well as agglutination of red blood cells during
the labeling process (4). Current NRC standards limit
the presence of this ion to IOµg (fission Mo"") and
20µg (activation Mo"") per milliliter of generator
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Fig. &-Chromatograph ofTc 09 m-Polyphosphate® used to produce
bone im age in Figure 4 demonstrates bound, reduced, and free
co mponents of the radiopharmaceutical.
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COMPATIBILITY OF KIT SOURCE AND RADIONUCLIDIC BINDING EFFICIENCY
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Fig. ?-Comparison of chromatographs obtained after preparation of two commercially available bone imaging agents; Tc" m-Pol yph osphate® (New England Nuclear), Tc••m-Osteoscan® (Proctor and Gamble) .

eluent. This represents a more stringent requirement
from a previous 500µg Al (III)/10 millicuries Tc99 mpertechnetate limitation.
To determine at what concentration of Al (III)
flocculation of sulfur colloid would occur, Al (Ill)
solution was prepared by dissolving 99+% aluminum
metal in HCI. Aluminum (III)-Tc 99 m-pertechnetate
solutions were prepared such that Al (III) concentration ranged from lOµg/ml to lOOOµg/ml of Tc 99 mpertechnetate in saline (Fig. 10). A control using Al
(III) free pertechnetate was also prepared. Technetium-99m-sulfur colloid (Squibb) were prepared
by standard methods incor,porating each of the Al
(III)-Tc99 m-pertechnetate solutions as the radioactive
source. Final sulfur colloid volumes were 8 ml giving
resultant Al (III) concentrations of O to 12.50 mg%.
Aluminon reagent (aurin-tricarboxylic acid) test
strips (NEN) were evaluated for suitability in the

detection of Al (Ill) contamination at levels associated with sulfur colloid flocculation (Fig . 11 ).
Colloid aggregation was determined by placing 0.1
ml of each sample on a standard hemocytometer
chamber and observation under light microscopy
(Fig. 12).
Two hundred microcuries (0.2 ml) of each of the
sulfur colloid preparations were injected into 250 g
female Sprague-Dawley rats via a femoral vein . Scintiphotos were obtained using the Searle Radiographies .Pho-Gamma HP camera fitted with a pinhole collimator to demonstrate distribution of the
radiocolloid (Fig. 13).
Preparations of sulfur colloid from O to 0.63
mg% Al (Ill) demonstrated no aggregation. Aluminon test papers demonstrated an increase in the presence of Al (III) with each increase in ion concentration . Scintiphotos of test animals demonstrated
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Fig. 8-Chromatographs obtained following development of Tc••m-Sn-Glucoheptonate® (New England Nuclear) in two solvent systems.
Upper chromatograph demonstrates absence of free pertechnetate. Lower chromatograph demonstrates absence of colloid.

distribution of radiocolloid to liver with no uptake in
lung. At 0.94 mg% Al (III), some colloid aggregation
was present with minimum uptake of colloid in the
lung of test animal. At 1.56 mg% Al (III), aggregate
size became critical with scintiphotos demonstrating
significant quantities of radiocolloid in lung. Lung
uptake of radiocolloid increased at 3.13 mg% Al (III).

Test materials containing 6.25 mg% and 12.50 mg%
Al (III) demonstrated larger aggregates; however,
these materials were not administered to test animals
because aggregates would be limited to the inside
diameter (254µ) of the 25 G needle.
Liver, lung, and spleen from each test animal
were excized and counted using a Picker well counter.
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Aluminum Ion Spot Test
Aluminon Reagent Paper

TOXICOLOGY ALUMINUM CONTAMINATION IN
PERTECHN ET ATE
A.E.C. LIMIT - lOµg./ml. NaTc04

NaTc99mo
4

I. V. LD50 OF ALUMINUM (AS AICJ 3) IN MICE IS
79 mg./Kg. (EQUIVALENT TO ABOUT 20 mg.

Control

ALUMINUM/Kg.)

I.V. LD2 OF ALUMINUM (AS AICl 3) IN MICE IS
55 mg./Kg. (EQUIVALENT TO 14 mg. ALUMINUM/Kg.)

Fig. 9-Nuclear Regulatory Commission (AEC) allowable limit
for aluminum ion contamination in Tc 00 m-pertechnetate. Limit is
within a margin of safety for administration to man.

Ratios of counts for liver: lung and liver: spleen were
calculated (Fig. 14) and demonstrated good correlation with Squibb Institute reports for the control
material. At Al (III) concentration of 0.13 mg% to
0.94 mg%, there was a general increase in liver: lung
with a corresponding general decrease in liver: spleen.
Sulfur colloid used in liver imaging vary in size from
mµ to I µ. Up to 15% of the material may normally
localize in bone marrow attributable to the smaller
end of colloid size range. With increasing concentrations of Al (III), smaller colloid may aggregate
providing for more liver localization. Similarly, as the
colloid size continues to increase, more of the
material may localize in spleen, which is capable of
phagocytizing colloid larger than that by liver.
At the critical concentration of 1.56 mg% Al
(Ill), liver: lung was 0.32: I demonstrating on a pergram basis three times the activity of radiocolloid in
lung as compared to liver. At 3 .13 mg% Al (III), activity in the lung increased to 16 times that of liver.
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* FINAL PREPARATION = 8 ml.

Fig. IO-Concentration of aluminum ion in radioactive solutions.
Center panel expresses aluminum concentration present in Tc 00mpertechnetate. Third panel expresses aluminum concentration
present following preparation of sulfur colloid kit.

125JJgAl+3/ml.
250JJgAl+3/ml.
500pgA1+3 /ml.
1000pgAl+3/ml.
Fig. I I-Change in aluminon spot test with increasing concentration of aluminum ion.

In conclusion, the Aluminon test papers were
adequate in detecting Al (III) concentration, and the
maximum allowable concentration of Al (III) in
Tc••m-pertechnetate was found to be 75µg/ml. The
current standard is well within this value.
Biological Controls. The United States Pharmacopeia (USP) specifications for all parenteral
products includes the absence of viable forms of
bacteria, viruses, yeast, and molds as well as
pyrogenic substances. Therefore, radiopharmaceuticals administered parenterally must also be of this
quality.
A. Sterility. Many of the radiopharmaceuticals
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3.13mg.0/oAl+3
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Fig. 12-Effect of increasing concentration of
aluminum ion on colloid aggregation. Magnification is IOX.
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0.13mg. 0/oAl+3

Omg. 0/0A1+3

0.63mg.0/oAt+3

0.31mg. 0/oAt+3

0.94mg.0/oAt+3 _

3.13mg.0/oAl+3

1.56 mg. 0/o A1+3

Fig. 13-Effect of increasing concentration of aluminum ion on
radiocolloid distribution in rat.
Anterior views obtained with
Searle Radiographies-HP gamma
camera fitted with a pin-hole
collimator. Each image represents
the accumulation of 100,000
counts.
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Effect of Al+ 3 Content in Tc99m - Sulfur Colloid on
Distribution Ratios* in Rat Organs (per gram wt.)

.!!19· % Al+3

Liver:Lung

Liver: Spleen

0

4.73: l

1. 23:l

0. 13

6.73:l

6.43: l

0.31

5,23:l

4.77: l

0.63

3.46: l

1.83:l

0.94

4.81:l

1.59:l

l.56

0.32:l

1.16:l

3.13

0.06: l

0 . 37:l

* 20 min. post-injection (i.v.)
Fig. 14-Ratios ofliver:lung and liver:spleen counts obtained from
excized rat organs. Ratios are expressed per-gram weight of organ.

used as diagnostic agents in nuclear medicine are intended for parenteral administration. Pharmaceuticals of this type must meet USP requirements
in that they are sterile, apyrogenic, and of acceptable
pH (5).
Methods of sterilization vary and selection is
dependant upon stability of the compound and its
label. Terminal sterilization in an autoclave and
membrane filtration are two of the more commonly
used methods employed to sterilize radiopharmaceuticals. With each of the above methods,
however, samples must be taken and tested to confirm sterility.
The USP method requires innoculation of the
radiopharmaceutical into fluid thioglycolate and
Soybean-Casein Digest medias. A 7-day incubation
period at 30 to 35 °C with fluid thioglycolate and 20 to
25°C with Soybean-Casein Digest without evidence of
viable organisms indicates a sterile preparation. It
becomes apparent that activity of radiopharmaceuticals with short physical half-lives would significantly
decay before the product was approved for clinical
use. Under this circumstance, the dilemma of whether
to administer the preparation may be minimized if
asceptic technique were employed and previous
materials tested after-the-fact demonstrated sterility.
Work by Deland and Wagner (6) has shortened
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the determination of sterility to within acceptable
time for short-lived nuclides. Test materials are innoculated in thioglycolate broth containing C 14
glucose. Viable organisms, if present, would
metabolize the labeled sugar to C1 4 0 2 which is
detected and recorded, demonstrating the presence of
microbial contamination. This procedure, although
not an official test, has reduced lag time from days to
1-3 hours.
B. Apyrogenicity. Pyrogens of microbial origin,
are mucopolysaccharide molecules present as the
result of bacterial, viral, fungal, or yeast contamination . The substances are heat-stable and therefore
resistant to destruction by terminal sterilization.
When administered by some injection route, they
may produce in man such symptoms as mono-or
biphasic fever, chills, malaise, mild to moderate pain
in the joints, and leukopenia, or other less well-defined
clinical signs, such as apprehension, pallor, and substernal oppression (7). Sensitivity of the human body
to administration of pyrogens by the intrathecal
route is such that the biologic insult of this type increases 4000-fold as compared to the intravenous
route (8).
The USP method for the detection of pyrogens
relies upon rectal temperature change in the pre- to
post-innoculated rabbit. Controls for the test are
stringent and include:
I. Use of healthy, mature rabbits each weighing
not less than 1.5 kg that have maintained this
weight for one week.
2. Control temperature of each rabbit used does
not vary by more than 1°C from each other.
No animal may be used with a control
temperature exceeding 39.8°C.
3. Animals must be housed individually, free
from excitement, in an environmental temperature that does not vary by more than
± 3oc.
4. Animals may not be used more than once
every 48 hours.
5. Animals may not be used before 2 weeks having been given a test sample that was
pyrogenic.
6. Animals not used for pyrogen testing during a
14-day period must be sham tested 1-3 days
before use.
7. Test material administered may not exceed 10
ml.
Test material is injected into the marginal ear
vein of three animals. Rectal temperatures are
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recorded at hourly intervals for three hours post injection. If none of the test animals show an individual
temperature rise of 0.6°C or more above its control
temperature and if the sum of the temperature rises in
all three animals does not exceed l.4°C, the test
material meets the requirement of apyrogenicity. If
the above criteria are not met, the test must be
repeated with five rabbits. If not more than three of
the eight rabbits show temperature rises of 0.6°C or
more and if the sum of the eight temperature rises
does not exceed 3.7°C, the product under test meets
the requirement for apyrogenicity.
Pyrogen testing by the USP method is difficult,
time consuming, and generally not amenable to small
laboratories. Cooper et al (9), have introduced an in
vitro test based on the detection of endotoxin
through gelation of Limulus polyphemus lysate
prepared from blood amebocytes. Test results may be
obtained in I hour which represents time saved with
respect to short-lived nuclides. This test is significantly more sensitive than the official test; however, it
is subject to false positive results if the preparation to
be tested contains Ca (II). The problems of adopting
a more sensitive test must be justified in view of the
fact that no documentation exists of pyrexia following administration of materials found apyrogenic by
the USP test. The question of how sensitive pyrogen
testing must be deserves further investigation.
C. Safety. With the administration of pharmaceuticals in radioactive form, safety includes
radiation-absorbed doses received by target and nontarget organs that are within acceptable limits. The
product must also be nontoxic in doses administered
with respect to formed cells in blood as well as organs
to which the material will be distributed.
D. Affinity. Radioactive compounds used in
organ imaging localize by various physiological
mechanisms . Control of the physiochemical
characteristics of the radiopharmaceutical are needed
to assure affinity of the product for target organs.
Soloway and Davis ( I 0) reviewed radiopharmaceuticals currently used for organ imaging and
have catagorized their biological basis for localization . In vitro quality control testing is essential to
predetermine that organs of interest will be
visualized . Poor affinity demonstrated by suboptimal
images must frequently be repeated, therefore, necessitating subsequent dosing with radionuclides and increased radiation burden to patients.
Perfusion lung imaging is dependant upon blood
flow to that organ with capillary and terminal

arteriolar blockage by radiolabeled particles. Particles for this purpose must be larger than that of red
blood cells (7µ) to prevent arterial distribution after
intravenous administration . To avoid an unnecessarily long, effective half-life in lung, as well as optimum patient safety, particles should be limited in
size to 50µ. Particle size determination can be easily
accomplished in the laboratory using light
microscopy as a routine check.
Images of liver and spleen are dependant upon
blood flow to these organs with phagocytosis of
radiocolloid by reticuloendothelial cells. Colloid of
0.6µ and 1.0µ are necessary for localization in liver
and spleen respectively. Although colloid may not be
visualized by light microscopy, the test serves as a
negative check for aggregates so large that they might
localize in lung.
Radioactive materials have been used to
delineate special anatomic or biochemical compartments. Labeled serum albumin has been used in the
past for cisternography and currently for blood pool
imaging. Care must be taken not to denature the
protein by excessive labeling or chemical manipulation.
Stannous chloride [Sn{II)] has become a useful
reducing agent in the preparation of technetiumlabeled radiopharmaceuticals. Yano et al {11), in
studies with the bone imaging agent Tc99 m-Sn-EHDP,
found optimum molar ratio of Sn (11):EHDP for
greater bone localization and rapid soft tissue
clearance. They reported the importance in the order
of combination of EHDP, Sn (II) and Tc 99 mpertechnetate such that poor formulation resulted in
radiocolloid formation with localization in liver.
Poor localization of other technetium products with
significant uptake in thyroid has been noted when
stannic chloride [Sn(III)] forms on crystal surfaces of
the reducing agent.
Physical Controls.
A. Radioactive concentration. Refers to the activity concentration of the product with respect to activity per unit volume. Activity concentration can be
easily determined using a dose calibrator. This instrument has an overall accuracy of 5% and is designed to
quantitate many of the more commonly used
radionuclides.
B. Radioactive purity. This term should be discontinued in favor of the more accurate term
"radionuclide purity." It may be defined as that
proportion of the total activity that is present as the
stated radionuclide.
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The NRC limit for Mo 99 contamination has been
set at I microcurie Mo 99 per millicuries Tcgem_pertechnetate and 5 microcuries per dose of Tc 99 mpertechnetate. On a milligram basis the amount of
Mogg necessary for a lethal dose or LD 00 dose
in test animals is large as compared to what can
be eluted from an intact generator system (Fig. 15).
However, on an equal activity basis using the MIRO
system (12, 13), radiation burden from Mo 99 is 35
times greater as compared to Tc 99 m. It has also been
demonstrated that parent Mo 99 produced by neutron
activation of Mo 98 results in Cs 134 contamination.
Radioactive contaminants of Mo 99 -Tc 99 m
generator systems may be detected radiometrically .
Molybdenum-99 emits 740 and 780 kev gammas as
well as other less energetic photons. A 4 mm lead
shield adapter inserted in the ion chamber of the dose
calibrator would absorb all but 0.0002% of Tc 99 m
gamma (140 kev) and 50% of Mo 99 gamma (14). It is
fortuitous that Mo 99 activity can be read directly on
the Tc 99 m setting when the pertechnetate source is
placed in the lead adapter. The method allows for
quantitation of the Mo 99 activity which should not
exceed 0.1 % of the Tc 99 m activity. Cesium-134 emits
605 and 796 kev gammas which penetrate the 4 mm
lead shield and will be quantitated with the Mo99
reading.
In-House Preparation of Radiopharmaceuticals.

Present day practice of nuclear medicine relies
upon readily available organ-specific radiopharmaceuticals. Exhaustive research of natural and manmade radionuclides has resulted in a handful that
demonstrate organ specificity with patient safety. As
a result, research has been directed toward the labeling of molecules with radionuclides of near-ideal
properties for organ selectivity. Technetium-99m
having suitable physical, chemical, and biological
properties enjoys an active role in organ imaging.
Since 1961, many Tc 9 em-labeled compounds have
been introduced which have broadened the
diagnostic capabilities of nuclear medicine and/ or
improved radiation burden as compared to
previously used radionuclides.
Much of this research has resulted in the commercial availability of kit preparations where simple asceptic techniques are employed to produce the
desired Tc99 m radiopharmaceutical. With the commercial availability of Mo99 -Tc99 m generators, daily
delivery, or MEK extraction techniques, a continuous supply of Tc 99 m-pertechnetate is at hand for

Tox icolog y of Radionuclidic Impurities in Pertechnetote

M/9

9Sh,

NRC Limit - l µCi M/9 / mCi Tc
99
99m
5 µCi Mo
/ dose Tc
I . P. lethol dose of Mo (os No/kO 4 ) in rote is obout

114 - 117 mg. Mo/ Kg .
I. V. LO 50 of Mo ( as Na 2 MoO 4 ) in mice is obout 248 mg ./ Kg .

(equi valent to 116 mg . Mo/ Kg. )
No effe c t dose in mice is about 28 mg. / Kg .

Cs 134
NRC Limit - 20µCi (total bod y burden )

Fig . 15-Nuclear Regulatory Commission maximum allowable
limits for radionuclidic impurities in Tc••m-pertechnetate.

the preparation of kits. The commercial availability
of these tools has been a boon to many institutions
which might not be able to provide this diagnostic service. This availability, however, is not without cost,
and newer formulations with clinical merit may
take months before they become commercially
available, thereby limiting diagnostic studies to current available preparation.
Radiopharmaceutical scientists (radiopharmacist, radiochemist) have paralleled the growth of
nuclear medicine consultants by providing efficacious
radiopharmaceutical diagnostic agents. In-house
preparation of radiopharmaceuticals by these individuals have allowed for the availability of newer
agents in nuclear medicine practice. Institutions
preparing radiopharmaceuticals are increasing, and
those without this technical capability may benefit
under a cost-sharing program ( 15).
Several formulations are available for the
preparation of the more routinely used imaging
agents . The following are currently used at the
Medical College of Virginia Hospitals. Drug-adverse
reactions have not been reported for any of the
products since clinical initiation.
PREPARATION OF Tc99M-SULFUR COLLOID KIT (16)
Solution A:
To 100 ml of Sterile Distilled Water add:
I. 400 mg Sodium Thiosulfate
2. 750 mg Gelatin
3. 850 mg Potassium Monohydrogen Phosphate (Dibasic)
4. 200 mg Disodium Edetate
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Stir and warm the mixture gently to dissolve the
gelatin. After solution is complete, pipette exactly 3 ml of the solution into each 30 ml serum
vials. Seal the vials with rubber closures and
aluminum caps (twice boiled in sterile distilled
water for not less than 30 minutes and autoclaved, wrapped in aluminum foil) and autoclave
Solution A for 15 minutes at 20 PSIG pressure.

PREPARATION OF Tc99M-LABELED HUMAN SERUM
ALBUMIN (17)
Materials:

I.

Solution B:
Sterilize 1-3 ml of exactly 0.5N HCI solution in
serum vials by autoclaving for 15 minutes at 20
PSIG pressure.
II.
Solution C:
To 100 ml Sterile Distilled Water add:
I. 1.20 g Sodium Hydroxide pellets
2. 2.8 g Sodium monohydrogen phosphate
Mix well until solution is complete. Do not
autoclave. Sterilize by filtration using 0.22µ
membrane filter.

III.

Procedure:

I.

PREPARATION OF Tc99M MAA KIT (16)
A. Prepare Albumin Sodium Acetate solution
in distilled water such that it contains IO
mg/ml of HSA, 100 mg/ ml of Sodium
Acetate. Sterilize by membrane filtration
(0.22µ size).
B. Prepare Stannous Chloride solution in IN
HCI such that it contains 5 mg/ ml of stannous chloride. Sterilize by membrane filtration (0.22µ size).
C. To an empty sterile serum vial containing a
small magnetic stirrer mix 5 ml of Solution A
with 19 ml of Sterile Water for Injection.
Mix well. Add I ml of Solution B. The pH
should be approximately 5.5.
D. Macroaggregate the Albumin in the above
solution in a water bath at 80°C± I for 12
minutes with stirring.
E. Cool and mix the aggregates well. Each ml
of this preparation now contains:
I. 2 mg HSA as aggregates (denatured)
2. 200µg Stannous Chloride as hydroxide
3. 20 mg Sodium Acetate as buffer
F . Transfer under aseptic conditions I ml each
of this solution to presterilized empty serum
vials and store under refrigeration.

Kit (consists of 3 sterile pyrogen-free vials).
Vial "A"-20 ml vial containing 0.85 ml
of IN HCL with two I-inch lengths of Zr
wire inserted through the diaphragm.
Vial " B" -5 ml containing approximately
I ml of HSA 25%.
Vial "C"-5 ml vial containing approximately 2 ml of Sodium Bicarbonate 3.75%
and Sodium Hydroxide 2.0% in sterile
pyrogen-free water for injection .
Lead pig (for housing 200 ml vial during
procedure).
D.C. power source with external leads
adapted with alligator clips capable of
providing 100 milliamps constant current
at 3-5 volts .

Place vial "A" in lead pig; electrically insulate the top of the container by covering
top of lead pig and aluminum band with
masking tape. Rubber diaphragm is left exposed.
II. To vial "A" aseptically add 5.5 ml of
pertechnetate in normal saline (oxident
free). Remove 5.5 ml air.
III. To vial "A" aseptically add 0.1 ml ofHSA
from vial "B" using a I ml TB syringe
adapted with a 21 G needle. Flush syringe
several times and remove 0.1 ml of air.
IV. Immediately connect electrodes to power
supply leads by means of alligator clips.
Invert vial allowing contents of vial to
V.
come in contact with both electrodes.
VI. Using circular motion gently agitate the inverted vial. Pass l 00 milliamps of current
for exactly 42 seconds; continue to agitate
vial inverted position for an additional 15
seconds after electrolysis is completed.
VII. Remove leads from electrodes, reinvert vial
to upright position and allow vial "A" to
incubate at room temperature for at least
30 minutes.
VIII . Add to vial "A" 1.2 ml of vial "C" .
Remove an equivalent amount of air.
IX. Pass the product through a 0.22µ
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membrane filter and collect in a sterile
empty vial.

8. ATKINS E: Pathogenesis of fever. Physiol Rev 40:580-646,
1960.

Radiopharmaceuticals, whether prepared inhouse or obtained commercially, should be subjected
to quality control testing. If the limitations of image
interpretations are instrumentation, technique, adequate patient history, and radiopharmaceutical
quality, equal attention must be payed to all.

9. COOPER JF, LEVIN J, WAGNER HN JR: New, rapid, in-vitro
test for pyrogen in short-lived radiopharmaceuticals,
abstracted. J Nucl Med 11:310, 1970.
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